Close

Gilead Sciences (GILD) Announces Positive Phase 2 Results for GS-9674 in Primary PSC at The Liver Meeting

November 9, 2018 8:00 AM EST Send to a Friend
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login